Showing results (1-10 of 362) with videos related to
Sort By:
Pageof 37
Cancer Treatment Reviews|April 14, 2010
Targeting DNA repair in breast cancer: a clinical and translational updateEitan Amir, Bostjan Seruga, Rosario Serrano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Failures in Phase III: Causes and ConsequencesBostjan Seruga, Alberto Ocana, Eitan Amir, et al.Mayo Clinic Proceedings|January 7, 2019
Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2013
Phase III trials of targeted anticancer therapies: redesigning the conceptAlberto Ocana, Eitan Amir, Francisco Vera-Badillo, et al.Oncology|November 20, 2017
Reporting of Randomized Trials in Common Cancers in the Lay MediaDomen Ribnikar, Hadar Goldvaser, Alberto Ocana, et al.Journal of the National Cancer Institute|December 11, 2012
HER3 overexpression and survival in solid tumors: a meta-analysisAlberto Ocana, Francisco Vera-Badillo, Bostjan Seruga, et al.Breast Cancer Research and Treatment|May 11, 2010
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysisBostjan Seruga, Eitan AmirPlos One|March 28, 2015
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyAmirrtha Srikanthan, Josee-Lyne Ethier, Alberto Ocana, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2018
Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled TrialsDaniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysisSaroj Niraula, Eitan Amir, Francisco Vera-Badillo, et al.Pageof 37